OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.

But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.

If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.

The company defends its cancer strategy, and says it's not a me-too developer.

First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.

The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.